Roche and MorphoSys expand therapeutic antibody partnership
Roche and MorphoSys have entered into a collaboration to develop new therapeutic antibodies in oncology.
Roche and MorphoSys have entered into a collaboration to develop new therapeutic antibodies in oncology.
Expanding on a relationship in Alzheimer's disease, which began in September 2000, Roche will elect new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL GOLD technology.
Under the terms of the agreement, Roche and MorphoSys will collaborate on two new antibody programmes in oncology. Roche will be responsible for preclinical and clinical development as well as subsequent marketing of all resulting products. MorphoSys will receive an upfront payment and may receive additional research funding and future event payments totaling more than Euro 10 million per programme, plus potential royalties.
'Extending our active alliance shows a constructive working relationship between Roche and MorphoSys,' said Peter Hug, Roche's global head of pharma partnering. 'We are pleased to collaborate with a proven partner in a new therapeutic area.'